Mitsuko Miyamoto
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Mitsuko Miyamoto has a total of 21 co-authors. Here are the top co-authors by number of shared publications:
Naohiro Yamada
Pharmaceutical Research Laboratories, Toray Industries, Kamakura, Japan
2 shared publicationsAtsushi Ohtake
Pharmaceutical Research Laboratories, Toray Industries, Kamakura, Japan
1 shared publicationAtsushi Otake
11Pharmaceutical Research Laboratories, Toray Industries, Inc., 1111 Tebiro, Kamakura, 248-8555 Japan
1 shared publication- Hajimu Kurumatani
Toray Industries, Inc. Tokyo Japan
1 shared publication - Katsuhiko Iseki
Pharmaceutical Research Laboratories, Toray Industries Inc., 6-10-1 Tebiro, Kamakura, Kanagawa 248-8555, Japan
1 shared publication Kazuo Umemura
22Department of Pharmacology, Hamamatsu University School of Medicine, 1-20-1 Handayama, Hamamatsu, 431-3192, Japan
1 shared publication
Latest Publications
- Open Access
Synthesis of Novel IP Agonists via N-Aminoethyl Cyclic Amines Prepared by Decarboxylative Ring-Opening Reactions
An efficient synthesis of a highly potent and selective IP (PGI2 receptor) agonist that is not structurally analogous to PGI2 is described. This synthesis is accomplished through the following key steps: Nucleophilic ring-opening of 3-(4-chlorophenyl)-oxazolidin-2-one prepared by a one-pot procedure with 4-piperidinol and selective O-alkylation of 1-(2-(4-chlorophenylamino)ethyl)piperidin-4-ol. The obtained compound is a potent and selective IP agonist displaying a long duration of action.
Open AccessSynthesis of Novel IP Agonists via N-Aminoethyl Cyclic Amines Prepared by Decarboxylative Ring-Opening Reactions
An efficient synthesis of a highly potent and selective IP (PGI2 receptor) agonist that is not structurally analogous to PGI2 is described. This synthesis is accomplished through the following key steps: Nucleophilic ring-opening of 3-(4-chlorophenyl)-oxazolidin-2-one prepared by a one-pot procedure with 4-piperidinol and selective O-alkylation of 1-(2-(4-chlorophenylamino)ethyl)piperidin-4-ol. The obtained compound is a potent and selective IP agonist displaying a long duration of action.
- 1 January 2010
- Published by Georg Thieme Verlag KG in Thrombosis and Haemostasis
- Vol. 104 (10) , 788-795
TRA-418, a thromboxane A2 receptor antagonist and prostacyclin receptor agonist, inhibits platelet-leukocyte interaction in human whole blood
TRA-418, a compound with both thromboxane A2 receptor (TP receptor) antagonistic and prostacyclin receptor (IP receptor) agonistic activities, was synthesised in our laboratory as a new antithrombotic agent. In this study, we examined the effects of TRA-418 on platelet-leukocyte interactions in human whole blood. Platelet-leukocyte interactions were induced by U-46619 in the presence of epinephrine (U-46619 + epinephrine) or with thrombin receptor agonist peptide 1–6 (TRAP). Platelet-leukocyte interactions were assessed by flow cytometry, with examination of both platelet-neutrophil and platelet-monocyte complexes. In a control experiment, the TP receptor antagonist SQ-29548 significantly inhibited the induction of platelet-leukocyte complexes by the combination of U-46619 and epinephrine, but not TRAP-induced formation of platelet-leukocyte complexes. Conversely, the IP receptor agonist beraprost sodium inhibited platelet-leukocyte complex formation induced by both methods, although the IC50 values of beraprost sodium for U-46619 + epinephrine were at least 10-fold greater than for TRAP. Under such conditions, TRA-418 inhibited both U-46619 + epinephrine-induced and TRAP-induced platelet-leukocyte complex formation in a concentration-dependent manner, in a similar range. These results suggest that TRA-418 exerts its inhibitory effects on platelet-leukocyte interactions by acting as a TP receptor antagonist as well as an IP receptor agonist in an additive or synergistic manner. These inhibitory effects of TRA-418 on formation of platelet-leukocyte complexes suggest the compound is beneficial effects as an antithrombotic agent.
- 1 January 2010
- Published by Georg Thieme Verlag KG in Thrombosis and Haemostasis
- Vol. 104 (10) , 788-795
TRA-418, a thromboxane A2 receptor antagonist and prostacyclin receptor agonist, inhibits platelet-leukocyte interaction in human whole blood
TRA-418, a compound with both thromboxane A2 receptor (TP receptor) antagonistic and prostacyclin receptor (IP receptor) agonistic activities, was synthesised in our laboratory as a new antithrombotic agent. In this study, we examined the effects of TRA-418 on platelet-leukocyte interactions in human whole blood. Platelet-leukocyte interactions were induced by U-46619 in the presence of epinephrine (U-46619 + epinephrine) or with thrombin receptor agonist peptide 1–6 (TRAP). Platelet-leukocyte interactions were assessed by flow cytometry, with examination of both platelet-neutrophil and platelet-monocyte complexes. In a control experiment, the TP receptor antagonist SQ-29548 significantly inhibited the induction of platelet-leukocyte complexes by the combination of U-46619 and epinephrine, but not TRAP-induced formation of platelet-leukocyte complexes. Conversely, the IP receptor agonist beraprost sodium inhibited platelet-leukocyte complex formation induced by both methods, although the IC50 values of beraprost sodium for U-46619 + epinephrine were at least 10-fold greater than for TRAP. Under such conditions, TRA-418 inhibited both U-46619 + epinephrine-induced and TRAP-induced platelet-leukocyte complex formation in a concentration-dependent manner, in a similar range. These results suggest that TRA-418 exerts its inhibitory effects on platelet-leukocyte interactions by acting as a TP receptor antagonist as well as an IP receptor agonist in an additive or synergistic manner. These inhibitory effects of TRA-418 on formation of platelet-leukocyte complexes suggest the compound is beneficial effects as an antithrombotic agent.
- 1 September 2006
- Published by Elsevier in European Journal of Pharmacology
- Vol. 545 (2-3) , 173-176
Improvement of walking disturbance by beraprost sodium in rat femoral artery occlusion models
- 1 September 2006
- Published by Elsevier in European Journal of Pharmacology
- Vol. 545 (2-3) , 173-176
Improvement of walking disturbance by beraprost sodium in rat femoral artery occlusion models
- 1 November 2003
- Published by Wiley in British Journal of Pharmacology
- Vol. 140 (5) , 889-894
Effects of TRA‐418, a novel TP‐receptor antagonist, and IP‐receptor agonist, on human platelet activation and aggregation
{4‐[2‐(1,1‐Diphenylethylsulfanyl)‐ethyl]‐3,4‐dihydro‐2H‐benzo[1,4]oxazin‐8‐yloxy}‐acetic acid N‐Methyl‐D‐glucamine salt (TRA‐418) has both thromboxane A2 (TP)‐receptor antagonist and prostacyclin (IP)‐receptor agonist properties. The present study examined the advantageous effects of TRA‐418 based on the dual activities, over an agent having either activity alone and also the difference in the effects of TRA‐418 and a glycoprotein αIIb/β3 integrin (GPIIb/IIIa) inhibitor. TRA‐418 inhibited platelet GPIIb/IIIa activation as well as P‐selectin expression induced by adenosine 5′‐diphosphate, thrombin receptor agonist peptide 1–6 (Ser‐Phe‐Leu‐Leu‐Arg‐Asn‐NH2), and U‐46619 in the presence of epinephrine (U‐46619+ epinephrine). TRA‐418 also inhibited platelet aggregation induced by those platelet‐stimulants in Ca2+ chelating anticoagulant, citrate and in nonchelating anticoagulant, D‐phenylalanyl‐L‐prolyl‐L‐arginyl‐chloromethyl ketone (PPACK). The TP‐receptor antagonist SQ‐29548 inhibited only U‐46619+epinephrine‐induced GPIIb/IIIa activation, P‐selectin expression, and platelet aggregation. The IP‐receptor agonist beraprost sodium inhibited platelet activation. Beraprost also inhibited platelet aggregation induced by platelet stimulants we tested in citrate and in PPACK. The GPIIb/IIIa inhibitor abciximab blocked GPIIb/IIIa activation and platelet aggregation. However, abciximab showed slight inhibitory effects on P‐selectin expression. TRA‐418 is more advantageous as an antiplatelet agent than TP‐receptor antagonists or IP‐receptor agonists separately used. TRA‐418 showed a different inhibitory profile from abciximab in the effects on P‐selectin expression. British Journal of Pharmacology (2003) 140, 889–894. doi:10.1038/sj.bjp.0705499
- 1 November 2003
- Published by Wiley in British Journal of Pharmacology
- Vol. 140 (5) , 889-894
Effects of TRA‐418, a novel TP‐receptor antagonist, and IP‐receptor agonist, on human platelet activation and aggregation
{4‐[2‐(1,1‐Diphenylethylsulfanyl)‐ethyl]‐3,4‐dihydro‐2H‐benzo[1,4]oxazin‐8‐yloxy}‐acetic acid N‐Methyl‐D‐glucamine salt (TRA‐418) has both thromboxane A2 (TP)‐receptor antagonist and prostacyclin (IP)‐receptor agonist properties. The present study examined the advantageous effects of TRA‐418 based on the dual activities, over an agent having either activity alone and also the difference in the effects of TRA‐418 and a glycoprotein αIIb/β3 integrin (GPIIb/IIIa) inhibitor. TRA‐418 inhibited platelet GPIIb/IIIa activation as well as P‐selectin expression induced by adenosine 5′‐diphosphate, thrombin receptor agonist peptide 1–6 (Ser‐Phe‐Leu‐Leu‐Arg‐Asn‐NH2), and U‐46619 in the presence of epinephrine (U‐46619+ epinephrine). TRA‐418 also inhibited platelet aggregation induced by those platelet‐stimulants in Ca2+ chelating anticoagulant, citrate and in nonchelating anticoagulant, D‐phenylalanyl‐L‐prolyl‐L‐arginyl‐chloromethyl ketone (PPACK). The TP‐receptor antagonist SQ‐29548 inhibited only U‐46619+epinephrine‐induced GPIIb/IIIa activation, P‐selectin expression, and platelet aggregation. The IP‐receptor agonist beraprost sodium inhibited platelet activation. Beraprost also inhibited platelet aggregation induced by platelet stimulants we tested in citrate and in PPACK. The GPIIb/IIIa inhibitor abciximab blocked GPIIb/IIIa activation and platelet aggregation. However, abciximab showed slight inhibitory effects on P‐selectin expression. TRA‐418 is more advantageous as an antiplatelet agent than TP‐receptor antagonists or IP‐receptor agonists separately used. TRA‐418 showed a different inhibitory profile from abciximab in the effects on P‐selectin expression. British Journal of Pharmacology (2003) 140, 889–894. doi:10.1038/sj.bjp.0705499